Document is current
Any future updates will be listed below
-
Authors
Agarwal, Puneet https://orcid.org/0000-0003-1688-3840
Sampson, Avery https://orcid.org/0000-0001-7241-8770
Hueneman, Kathleen
Choi, Kwangmin
Jakobsen, Niels Asger https://orcid.org/0000-0002-5776-5085
Uible, Emma https://orcid.org/0000-0001-8301-1546
Ishikawa, Chiharu
Yeung, Jennifer
Bolanos, Lyndsey https://orcid.org/0000-0002-5447-5277
Zhao, Xueheng https://orcid.org/0000-0002-4156-3294
Setchell, Kenneth D.
Haslam, David B.
Galloway-Pena, Jessica
Byrd, John C.
Vyas, Paresh https://orcid.org/0000-0003-3931-0914
Starczynowski, Daniel T. https://orcid.org/0000-0002-5771-7462
- License Information
-
More Information
Article History
Received: 11 May 2023
Accepted: 26 March 2025
First Online: 23 April 2025
Competing interests
: D.T.S. serves on the scientific advisory board at Kurome Therapeutics; is a consultant for and/or received funding from Kurome Therapeutics, Captor Therapeutics, Treeline Biosciences and Tolero Therapeutics; and has equity in Kurome Therapeutics. K.D.S. is a consultant for Mirum Pharmaceuticals and Travere Therapeutics; and has equity in Asklepion Pharmaceuticals and Aliveris. J.C.B. is a consultant for Abbvie, Kura Oncology, Janssen, Newave, Syndax, Trillium, AstraZeneca, Novartis, Vincerx and Kronos; receives research funding from Pharmacyclics and Zencor; is a current equity holder in a private company and publicly traded company; is a current holder of stock options in a privately held company (Vincerx); and is chair of the scientific advisory board and a major stockholder in Vincerx Pharma. P.V. received research funding from Celgene. The other authors declare no competing interests.
